{"id":"menacwy-crm197","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain/erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W, and Y, each conjugated to CRM197 (a non-toxic diphtheria toxin variant). This conjugation enhances immunogenicity by promoting T-cell dependent B-cell responses, resulting in improved antibody production and immunological memory compared to unconjugated polysaccharide vaccines.","oneSentence":"MenACWY-CRM197 is a meningococcal conjugate vaccine that stimulates immune responses against serogroups A, C, W, and Y by conjugating polysaccharide antigens to a carrier protein (CRM197).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:40.169Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y"}]},"trialDetails":[{"nctId":"NCT05093829","phase":"PHASE3","title":"Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine","status":"COMPLETED","sponsor":"Emory University","startDate":"2022-03-24","conditions":"Meningitis","enrollment":1325},{"nctId":"NCT01192997","phase":"PHASE2, PHASE3","title":"Comparison of Two Meningococcal ACWY Conjugate Vaccines","status":"COMPLETED","sponsor":"Public Health England","startDate":"2012-06","conditions":"Meningococcal Meningitis","enrollment":91},{"nctId":"NCT01272180","phase":"PHASE2","title":"Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-08","conditions":"Invasive Meningococcal Disease","enrollment":484},{"nctId":"NCT02986854","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-12-08","conditions":"Infections, Meningococcal","enrollment":704},{"nctId":"NCT02287688","phase":"","title":"Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-12-01","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":144},{"nctId":"NCT01682876","phase":"PHASE3","title":"Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-07","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":715},{"nctId":"NCT01214837","phase":"PHASE3","title":"Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-10","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":751},{"nctId":"NCT00196976","phase":"PHASE2","title":"Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-24","conditions":"Infections, Meningococcal","enrollment":461},{"nctId":"NCT01148017","phase":"PHASE3","title":"Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-07","conditions":"Meningococcal Meningitis","enrollment":433},{"nctId":"NCT01973218","phase":"PHASE3","title":"Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-11","conditions":"Meningococcal Disease","enrollment":264},{"nctId":"NCT01018732","phase":"PHASE2","title":"A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-01","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":155},{"nctId":"NCT01367158","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-07","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":440},{"nctId":"NCT00601731","phase":"PHASE2","title":"Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-02","conditions":"Meningococcal Disease","enrollment":382},{"nctId":"NCT01823536","phase":"PHASE4","title":"Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-05","conditions":"Meningococcal Disease","enrollment":465},{"nctId":"NCT00262002","phase":"PHASE2","title":"Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2004-09","conditions":"Prevention of Meningococcal Disease","enrollment":601},{"nctId":"NCT01466387","phase":"PHASE3","title":"A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-11","conditions":"Meningococcal Disease, Meningococcal Meningitis, Typhoid","enrollment":552},{"nctId":"NCT00667602","phase":"PHASE3","title":"Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-03","conditions":"Meningococcal Meningitis","enrollment":662},{"nctId":"NCT00806195","phase":"PHASE3","title":"Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-12","conditions":"Meningitis, Meningococcal Infection","enrollment":7744}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MenACWY-CRM197","genericName":"MenACWY-CRM197","companyName":"Novartis","companyId":"novartis","modality":"Biologic","firstApprovalDate":"","aiSummary":"MenACWY-CRM197 is a meningococcal conjugate vaccine that stimulates immune responses against serogroups A, C, W, and Y by conjugating polysaccharide antigens to a carrier protein (CRM197). Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}